Munch MW, Myatra SN, Vijayaraghavan BKT, et al. - In view of the possibility that a higher than recommended daily dose of 6 mg of dexamethasone may be more beneficial in patients with severe and critical COVID-19, researchers conducted a randomized trial investigating the effects of 12 mg vs 6 mg of dexamethasone in these patients.

• A total of 1,000 patients with COVID-19 and severe hypoxemia were included.

• Outcomes revealed 22.0 days alive vs 20.5 days alive in correlation with receiving treatment with 12 mg/d vs 6 mg/d of dexamethasone, respectively.

• This indicates no statistically significant difference concerning the days alive between the two treatments.